Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
International collaborative protocol for treatment of childhood and adolescent acute lymphoblastic leukemia
2007-004270-43Phase 3Completed
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- Oct 2009
- Modality
- Small Molecules, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of daunorubicin and pegaspargase in acute lymphoblastic leukemia (ALL) and B cell acute lymphoblastic leukemia (B-ALL) (3 arms), sponsored by Universitätsklinikum Schleswig-Holstein. Primary endpoints: Event-free survival and Toxicity reduction. Started Oct 2009; status: completed.
02
Drugs
daunorubicinpegaspargase
03
Conditions
acute lymphoblastic leukemia (ALL)B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on 2007-004270-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004270-43.